These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1008 related articles for article (PubMed ID: 22510238)

  • 1. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.
    Schneider T; Gleissner J; Merfort F; Hermanns M; Beneke M; Ulbrich E
    J Sex Med; 2011 Oct; 8(10):2904-11. PubMed ID: 21771281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
    Giuliano F; Oelke M; Jungwirth A; Hatzimouratidis K; Watts S; Cox D; Viktrup L
    J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
    Lojanapiwat B; Permpongkosol S
    Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
    BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials.
    Sperling H; Gittelman M; Norenberg C; Ulbrich E; Ewald S
    J Sex Med; 2011 Jan; 8(1):261-71. PubMed ID: 20807322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.